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concerning validation of IOTA
ADNEXmodelDear Editor,
We carefully read the letter by Van Calster et al. (Van Calster et al.,
2016a) concerning our article (Van Calster et al., 2016a; Szubert et al.,
2016). We want to thank the authors for the valuable feedback on our
work, and we do appreciate it. However, some of the guidelines men-
tioned by the authorswere recently published, hence, we could not con-
form to them at the time of an arrangement of our research. We had
chosen a different methodology, which still remains mathematically
valid. Nevertheless, we carefully considered each comment, and cer-
tainly we agree with most of them. Thus, we extended our results to
gain a deeper insight into performance of the ADNEX model. We hope,
this new approach will facilitate drawing reliable conclusions. We are
aware that with a larger study group the results would be more valu-
able, and according to Van Calster et al., suggestion (Van Calster et al.,
2016a),we combined the datasets from two Centers, andwe performed
subsequent analysis.
1. Study group
The combined dataset consists of 327 patients, including 104 malig-
nant and 223 benign ovarian tumors. Comprehensive patients' charac-
teristics are presented in Supplementary materials (Tables 1 and 2). In
order to evaluate both versions of ADNEX model (with and without
CA-125) on the same group of patients, we imputed 9 missing values
of CA-125. This was done by the predictive mean matching in multiple
imputation with 100 datasets. We used age, menopause, morphology,
locules number, as cites, shadowing, number of papillary projections, le-
sionmax diameter and solid part max diameter as predictors. Statistical
evaluation was performed with use of software R version 3.3.1 (2016-
06-21).
2. Calibration
We investigated calibration for both ADNEX models. For ADNEX
with CA-125, the intercept and slope equal to −0.451 (−0.843,
−0.065) and 0.843 (0.684, 1.028), respectively. This may suggest that
predicted risks are on average overestimated (intercept b0). For
ADNEX without CA-125, the intercept and slope equal to −0.274
(−0.641, 0.089) and 0.805 (0.652, 0.979), respectively. Such results
may imply overﬁtting of the model (slope b 1). The aforementioned in-
tercept and slope narrowly deviate from the ideal values. For this rea-
son, the calibration plots should be investigated, however, accordingDOIs of original article: http://dx.doi.org/10.1016/j.gore.2016.09.003,
http://dx.doi.org/10.1016/j.ygyno.2016.06.020.
http://dx.doi.org/10.1016/j.gore.2016.10.009
2352-5789/© 2016 The Authors. Published by Elsevier Inc. This is an open access article underto Van Calster et al., a graphical assessment should be done with at
least 200 events and 200 nonevents(Van Calster et al., 2016b). This con-
dition is not fulﬁlled within the study group; hence, we omit a detailed
analysis of the plots (Fig. 1).
3. Results and discussion
In the current analysis, The ADNEX model with CA-125 had signiﬁ-
cantly higher AUC when compared to ADNEX without CA-125 (0.927;
95%CI 0.888–0.958 vs 0.907; 95%CI 0.868, 0.941; DeLong's test p =
0.009; see Table 3). This may suggest that lack of CA125 evaluation
leads to signiﬁcant drop of the performance. AUCs for both models re-
main high, however, the conﬁdence intervals are wide, so there is a
need to investigate this problem in further research.
In the primary study we investigated only 10% cutoff, as it was pro-
posed in the original report(Van Calster et al., 2014). However, ADNEX
model may work differently depending on ovarian cancer prevalence,
thus according to the guidelines by Van Calster et al., some clinical cen-
ters may prefer different cutoffs(Van Calster et al., 2015). For this rea-
son, we have extended our original results and we have performed
analysis of ADNEX at cutoffs from 3% to 30%.We have provided detailed
results of ADNEX performance according to various cut-offs in supple-
mentary materials (Tables 4 and 5). These are important ﬁndings of
our study, showing the highest accuracy of the model at 30% threshold.
This is in agreement with the guidelines by Van Calster et al. showing
that for tertiary centers 30% cut-off may be more appropriate (Van
Calster et al., 2015).
When tumor groups were analyzed in pairs, the achieved AUCs indi-
cated good overall performance. In general, the results conﬁrm good
polytomous discrimination from the ﬁrst study by Van Calster et al., and
were comparable to later ADNEX model evaluation studies (Table 6)
(Van Calster et al., 2014; Araujo et al., 2016; Meys et al., 2016; Sayasneh
et al., 2016). Both polytomous discrimination indexes (PDI) were N0.2,
which in this case is a threshold for a random performance. The models
had problems in discrimination between some groups: borderline vs
stage I, stage I vs stage II-IV, stage II-IV vs metastatic and in particular
stage I vs metastatic. However, low AUCs for these pairs might be caused
by the low prevalence of some malignant subclasses in the study group.
We gave a special attention to ‘multiclass’ performance evaluation.
VanCalster et al., provided guidelines for applyingADNEXmodel in clin-
ical practice. The authors “believe that the aim should not be to classify
tumors into a single subgroup of malignancy” and the risk should be
assessed per type of malignancy(Van Calster et al., 2015). However, in
our setting of external validation we were curious to know how
ADNEX models behave when they have to differentiate between ﬁve
categories. This can be achieved by the assessment of relative change
in risk, as it was described by the authors in the aforementioned article
(Van Calster et al., 2015). We have used prevalence of the total pooled
dataset described in the article by Van Calster et al.(Van Calster et al.,
2014). We have investigated the performance of the ADNEX models
with 10% cutoff (see Tables 7–10). Indeed, with the use of relative risk
calculation, such an approach improves the performance comparing tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
52 Correspondenceabsolute risk. However, many II-IV stage tumors are misclassiﬁed as
borderline tumors. There is also problem with metastatic tumors,
which are commonly misclassiﬁed as other malignant types. The latter
case might be investigated with a larger study group, since in this vali-
dation there are only 10 such cases. Nevertheless, the results conﬁrm
that the ADNEX models should not be used in that manner. Thus, we
speculate that the best method for evaluation of ADNEX performance
would be prospective analysis of clinical decision making upon
ADNEX results.
Appendix A. Supplementary data
Supplementary data to this article can be found online at doi:10.
1016/j.gore.2016.10.009.
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